Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca To Eliminate 1,400 Jobs In Europe Even As It Expands In China

This article was originally published in PharmAsia News

Executive Summary

BEIJING - AstraZeneca is expanding its main pharmaceutical manufacturing facility and logistics center in China even as the company prepares to close some smaller sites in Spain, Belgium and Sweden, according to AstraZeneca executives in the United Kingdom and China

You may also be interested in...



China's Medical Exports And Imports Nearly Double In First Half 2011

SHANGHAI - During the first half of 2011, China posted strong export and import growth in its medical products, which include pharmaceutical, active pharmaceutical ingredients, medical devices and traditional Chinese medicines, according to an Aug. 11 report from China's Chamber of Commerce

China's Medical Exports And Imports Nearly Double In First Half 2011

SHANGHAI - During the first half of 2011, China posted strong export and import growth in its medical products, which include pharmaceutical, active pharmaceutical ingredients, medical devices and traditional Chinese medicines, according to an Aug. 11 report from China's Chamber of Commerce

Investment Analysts Call On Western Drug Titans To Become More Transparent On Absolute Sales, Profit Levels In Emerging Markets

BEIJING - The globe's leading pharmaceutical players should become more transparent about precise sales and profit levels across emerging markets, including China, rather than issue vague statements about double-digit growth in these regions without providing base figures, according to investment analysts

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel